This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Catamaran Corporation Reduces Overall Drug Trend To 2.4 Percent In 2013

Catamaran reports lower overall trend, record-setting generic dispensing rate and greater cost controls

SCHAUMBURG, IL, April 16, 2014 /PRNewswire/ - Catamaran Corp. (NASDAQ: CTRX) (TSX: CCT), a leading provider of pharmacy benefit management (PBM) services and technology, released its 2014 Informed Trends™ report this morning. The report reveals a decrease in overall drug trend, from 2.6 percent (2012) to 2.4 percent (2013), a record-setting generic dispensing rate of 83.6 percent and progressive cost controls for Catamaran clients. The report also shows a negative 0.7 percent traditional trend driven by the adoption of generics for blockbuster drugs such as Singular ® and Lipitor ®.

"At Catamaran, we are enabling people to take charge of their health through our ability to leverage data and technology in new and innovative ways. This has allowed us to drive high levels of engagement and better outcomes for all stakeholders," said Mark Thierer, Chief Executive Officer at Catamaran. "We view each unique touch point as a moment of opportunity to make a difference - The Catamaran Difference."

Specialty trend, led by increased utilization for multiple sclerosis and other auto-immune diseases, was offset by a decrease in utilization for hepatitis C drugs as patients awaited new drug approvals, resulting in 14.3 percent overall trend. Specialty is expected to represent nearly a quarter of Catamaran's total drug volume by 2016. To manage this high-cost market segment, Catamaran's specialty pharmacy, BriovaRx™, takes a holistic approach to patient care offering hands-on, individualized support to patients.

"Our top performing clients in 2013 were our most highly managed, maximizing outcomes through our clinical programs across all market segments," said Sumit Dutta, M.D., MBA, Senior Vice President and Chief Medical Officer at Catamaran. "We are delivering smarter solutions, enabling critical connections and pioneering innovative interventions to empower our clients and members to maximize their healthcare dollar."

Moments of Opportunity, the theme of the report, showcases how Catamaran harnesses every opportunity to make a difference through personalized interventions and tailored solutions for clients and members. The trend report breaks down Catamaran's clinical approach of engaging nationally, locally and personally to create compelling results.

The full report, Moments of Opportunity, is available for download. High level insights can be found on the Catamaran trend portal and the company is also offering a webcast for a deeper understanding of the key takeaways on Tuesday, April 22, 2014, at 12:30pm Eastern time. To register, click here.

About Catamaran Catamaran, the industry's fastest-growing pharmacy benefits manager, helps organizations and the communities they serve take control of prescription drug costs. Managing more than 350 million prescriptions each year on behalf of over 32 million members, our flexible, holistic solutions improve patient care and empower individuals to take charge of their health. Processing one in every five prescription claims in the U.S., Catamaran's skill and scale deliver compelling financial results and sustainable improvement in the overall health of members. Catamaran is headquartered in Schaumburg, Ill., with multiple locations in the U.S. and Canada. For more information, please visit CatamaranRx.com, and for industry news and information follow Catamaran on Twitter, @CatamaranCorp.

SOURCE Catamaran

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,035.25 -35.97 -0.21%
S&P 500 1,974.50 -3.30 -0.17%
NASDAQ 4,496.9660 -8.8860 -0.20%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs